[{"id":"82e136f4-d38a-459f-8a3f-411cfccafc31","acronym":"","url":"https://clinicaltrials.gov/study/NCT05495464","created_at":"2022-08-10T12:55:30.197Z","updated_at":"2025-02-25T15:00:33.482Z","phase":"Phase 1","brief_title":"A Pilot \"Window-3\" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients with Previously Untreated High-risk Mantle Cell Lymphoma","source_id_and_acronym":"NCT05495464","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5","pipe":" | ","alterations":" CD20 positive • Chr t(11;14)","tags":["TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • fludarabine IV • Tecartus (brexucabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/18/2022","start_date":" 11/18/2022","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-12"},{"id":"825e707d-d24d-4a05-b786-1228f5cc02ad","acronym":"Window-2","url":"https://clinicaltrials.gov/study/NCT03710772","created_at":"2021-01-18T18:11:30.804Z","updated_at":"2025-02-25T15:34:12.058Z","phase":"Phase 2","brief_title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT03710772 - Window-2","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • NSD2","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • CD20 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 05/22/2025","primary_completion_date":" 05/22/2025","study_txt":" Completion: 05/22/2025","study_completion_date":" 05/22/2025","last_update_posted":"2025-02-11"},{"id":"08b82509-fbbd-4719-b2fe-d7db759f217f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05529069","created_at":"2022-09-06T17:03:18.330Z","updated_at":"2024-07-02T16:35:07.866Z","phase":"Phase 2","brief_title":"Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients","source_id_and_acronym":"NCT05529069","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification","tags":["TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Jaypirca (pirtobrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/25/2023","start_date":" 01/25/2023","primary_txt":" Primary completion: 04/28/2027","primary_completion_date":" 04/28/2027","study_txt":" Completion: 04/28/2027","study_completion_date":" 04/28/2027","last_update_posted":"2024-04-24"},{"id":"d1c65fef-f151-4887-8cfe-4cca4bc9b521","acronym":"","url":"https://clinicaltrials.gov/study/NCT03282396","created_at":"2021-01-18T16:12:27.906Z","updated_at":"2024-07-02T16:35:08.356Z","phase":"Phase 2","brief_title":"Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma","source_id_and_acronym":"NCT03282396","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • NSD2","pipe":" | ","alterations":" TP53 mutation • CD20 positive • TP53 wild-type • KMT2D mutation • MYC positive","tags":["TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive • TP53 wild-type • KMT2D mutation • MYC positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-04-22"},{"id":"e089e3f8-f160-47a9-a0b8-746650c303a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05861050","created_at":"2023-05-16T17:06:41.960Z","updated_at":"2024-07-02T16:35:30.746Z","phase":"Phase 1/2","brief_title":"Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma","source_id_and_acronym":"NCT05861050","lead_sponsor":"City of Hope Medical Center","biomarkers":" TP53 • CDKN2A • CCND1 • KMT2D • NOTCH2 • SOX11 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr t(11;14) • KMT2D mutation • CCND1 expression • SOX11 expression","tags":["TP53 • CDKN2A • CCND1 • KMT2D • NOTCH2 • SOX11 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr t(11;14) • KMT2D mutation • CCND1 expression • SOX11 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • lenalidomide • Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-11-01"},{"id":"2b0c88f6-665c-4f24-a753-369906ca5f37","acronym":"KTX-MMSET-001","url":"https://clinicaltrials.gov/study/NCT05651932","created_at":"2022-12-15T14:58:11.284Z","updated_at":"2024-07-02T16:35:31.911Z","phase":"Phase 1","brief_title":"A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma","source_id_and_acronym":"NCT05651932 - KTX-MMSET-001","lead_sponsor":"K36 Therapeutics, Inc.","biomarkers":" NSD2","pipe":" | ","alterations":" Chr t(4;14)","tags":["NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(4;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gintemetostat (KTX-1001)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/22/2023","start_date":" 02/22/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-10-24"},{"id":"6160affe-41bc-4a57-bb71-a5426702805e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04990778","created_at":"2021-08-04T13:53:08.284Z","updated_at":"2024-07-02T16:36:15.692Z","phase":"Phase 2","brief_title":"Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT04990778","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CCND1 • NOTCH2 • BIRC3 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • TP53 wild-type • TP53 deletion • BIRC3 mutation • CCND1 overexpression • CCND1 mutation","tags":["CCND1 • NOTCH2 • BIRC3 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • TP53 wild-type • TP53 deletion • BIRC3 mutation • CCND1 overexpression • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • eprenetapopt (APR-246)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 03/24/2023","primary_completion_date":" 03/24/2023","study_txt":" Completion: 03/24/2023","study_completion_date":" 03/24/2023","last_update_posted":"2022-03-10"},{"id":"7f75492d-5014-4c14-8adb-fc1954d87ad9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00577512","created_at":"2022-04-16T16:04:52.572Z","updated_at":"2024-07-02T16:37:16.187Z","phase":"Phase 2","brief_title":"2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE","source_id_and_acronym":"NCT00577512","lead_sponsor":"University of Arkansas","biomarkers":" NSD2","pipe":"","alterations":" ","tags":["NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • doxorubicin hydrochloride • cyclophosphamide • dexamethasone injection"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 04/01/2007","start_date":" 04/01/2007","primary_txt":" Primary completion: 04/01/2009","primary_completion_date":" 04/01/2009","study_txt":" Completion: 04/01/2009","study_completion_date":" 04/01/2009","last_update_posted":"2017-11-20"}]